| |
Interpretation algorithm
|
|---|
|
Inhibitor
|
DR_SEQAN
|
Retrogram
|
ANRS
|
HIVDB
|
RegaInst
|
|---|
|
Zidovudine (AZT)
|
2.8 (36)
|
0 (31)
|
0 (35)
|
0 (33)
|
2.8 (36)
|
|
Zalcitabine (ddC)
|
11.1 (99)
|
0 (20)
|
n.d.b
|
n.d.
|
1.4 (27)
|
|
Didanosine (ddI)
|
17.8 (118)
|
0 (21)
|
11.7 (94)
|
0 (30)
|
3.3 (30)
|
|
Lamivudine (3TC)
|
3.9 (51)
|
2.1 (48)
|
7.1 (56)
|
4.2 (48)
|
4.2 (48)
|
|
Stavudine (d4T)
|
12.1 (58)
|
2.9 (34)
|
0 (35)
|
0 (32)
|
0 (57)
|
|
Abacavir (ABC)
|
19.8 (81)
|
0 (24)
|
19 (84)
|
3.3 (30)
|
3.8 (26)
|
|
Nevirapine (NVP)
|
13.4 (67)
|
14.0 (50)
|
8.8 (68)
|
4.8 (63)
|
4.0 (50)
|
|
Delavirdine (DLV)
|
5.4 (93)
|
3.3 (61)
|
n.d.
|
3.4 (88)
|
3.2 (62)
|
|
Efavirenz (EFV)
|
11.5 (87)
|
12.8 (47)
|
10.8 (65)
|
1.6 (63)
|
6.3 (48)
|
|
Saquinavir (SQV)
|
8.9 (201)
|
8.1 (222)
|
30.0 (357)
|
6.4 (218)
|
14.4 (263)
|
|
Ritonavir (RTV)
|
4.6 (175)
|
5.4 (188)
|
6.5 (213)
|
4.1 (219)
|
7.6 (198)
|
|
Indinavir (IDV)
|
5.8 (190)
|
5.4 (185)
|
6.2 (211)
|
4.9 (205)
|
7.9 (228)
|
|
Nelfinavir (NFV)
|
5.6 (160)
|
6.0 (168)
|
13.9 (209)
|
2.9 (170)
|
13.0 (200)
|
|
Amprenavir (APV)
|
8.9 (223)
|
11.6 (216)
|
42.0 (483)
|
3.8 (208)
|
19.4 (304)
|
|
Lopinavir (LPV)
|
16.3 [0]c (43)
|
54.8 [28.6] (84)
|
61.6 [22.3] (112)
|
3.2 [3.2] (31)
|
37.5 [17.9] (56)
|
-
a The reported values are percentages of isolates that are predicted to be sensitive to the inhibitor (S category in Table 1), but show a fold-increase of the IC50 for the inhibitor, which is above the cut-off values given in Table 2. Numbers in parenthesis indicate the total number of isolates predicted to be susceptible to the drug in the analyzed data set.
-
b n.d., not determined.
-
c The numbers shown between brackets represent the percentages obtained using a 10-fold cut-off value.
